Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

NO_LONGER_AVAILABLE

Conditions studied: Mullerian Mixed Tumor of Ovary

In brief

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Key facts

Study ID

NCT02090127

Run by

AVEO Pharmaceuticals, Inc.

Last updated by the study team

2015-07-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Per original P05538 protocol

You may not qualify if…

• Per original P05538 protocol

Where it is running

• START — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.